SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63388 357 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
61393seekingalpha.complhky3465212/7/2022
61392Thanks for the link. Interesting, but as you no doubt know the road from a mouserickerickson-12/7/2022
61391Alzheimer’s sciencealert.comsysiphus212/7/2022
61390What has always bothered me about Avxl is that Missling seems like such a snake kdd999212/6/2022
61389gilead.comweatherproof612/6/2022
61388Accelerated Approval is often confused with "early approval." AA is baghettogoulash-12/6/2022
61387n.neurology.orgurslor-12/6/2022
61386Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilamerickerickson-12/6/2022
61385I don't think insurance will play a role in that, as I imagine insurance comweatherproof-12/6/2022
61384Good point. Only those without insurance would sign up for blinded trial vs offkdd999112/6/2022
6138311:03a ET 12/5/2022 - Dow Jones Small Drug Companies Could Face Squeeze From HarOlecranon-12/5/2022
61382I don't see why that can't happen after they get their recent results foweatherproof112/5/2022
61381Well, my question was, since the Rett's trials are farther along and likely kdd999-12/5/2022
61380No matter how you parse AVXL's data, I don't think there is any chance oghettogoulash-12/4/2022
61379This is a common problem in medical research. Authors trumpet "percent impstockdoc77-12/4/2022
61378I believe the author is bringing forward some of the criticisms out there and deweatherproof-12/4/2022
61377OK, I've gone thru the SA article and I find it more obfuscation that is difscorman1112/4/2022
61376I hope you're instincts are correct on the upward surge thing, Stew. That sweatherproof-12/4/2022
61375AVXL charts from presentation: AVXL slide deck Here it is clear, whereas the PRscorman1312/4/2022
61374Thanks, sysiphus. That was a good article. I think much of the ambiguity is exweatherproof112/4/2022
61373AVXL FWIW seekingalpha.comsysiphus212/4/2022
61372As my confusion on the Anavex data continues, I'm now thinking that the imprweatherproof212/3/2022
61371"In the first 50 study subjects who completed 12 months of open-label treatweatherproof112/3/2022
61370From IBD this afternoon: Anavex Catapults On Alzheimer's Results — What Thekdd999412/3/2022
61369Both can be true. You can have more patients in the study arm improving by at lweatherproof212/2/2022
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News